Pharvaris N.V. $PHVS Shares Purchased by Wellington Management Group LLP

Wellington Management Group LLP raised its position in Pharvaris N.V. (NASDAQ:PHVS) by 12.9% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,392,934 shares of the company’s stock after acquiring an additional 274,034 shares during the quarter. Wellington Management Group LLP owned approximately 3.66% of Pharvaris worth $82,748,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. California State Teachers Retirement System raised its holdings in shares of Pharvaris by 2.2% in the 4th quarter. California State Teachers Retirement System now owns 23,982 shares of the company’s stock valued at $666,000 after purchasing an additional 520 shares in the last quarter. JPMorgan Chase & Co. grew its stake in shares of Pharvaris by 30.6% during the second quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock worth $59,000 after purchasing an additional 783 shares in the last quarter. Quantbot Technologies LP acquired a new position in shares of Pharvaris during the second quarter worth $41,000. Public Employees Retirement System of Ohio increased its holdings in Pharvaris by 20.7% in the fourth quarter. Public Employees Retirement System of Ohio now owns 7,569 shares of the company’s stock valued at $210,000 after buying an additional 1,300 shares during the last quarter. Finally, Legal & General Group Plc increased its holdings in Pharvaris by 17.2% in the second quarter. Legal & General Group Plc now owns 11,550 shares of the company’s stock valued at $203,000 after buying an additional 1,695 shares during the last quarter.

Analysts Set New Price Targets

A number of analysts have issued reports on PHVS shares. Guggenheim lifted their price target on Pharvaris from $39.00 to $40.00 and gave the stock a “buy” rating in a report on Thursday, August 13th. New Street Research set a $60.00 target price on Pharvaris in a research report on Friday, August 14th. Wells Fargo & Company began coverage on Pharvaris in a research note on Wednesday, July 15th. They set an “overweight” rating and a $55.00 target price for the company. HSBC upgraded shares of Pharvaris to an “overweight” rating in a research note on Thursday, August 13th. Finally, Royal Bank Of Canada boosted their price objective on shares of Pharvaris from $51.00 to $52.00 and gave the stock an “outperform” rating in a research report on Thursday, August 13th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $51.08.

Insider Activity at Pharvaris

In other Pharvaris news, CEO Berndt Modig sold 2,292 shares of the firm’s stock in a transaction on Friday, August 14th. The shares were sold at an average price of $34.77, for a total transaction of $79,692.84. Following the transaction, the chief executive officer directly owned 130,625 shares of the company’s stock, valued at approximately $4,541,831.25. This trade represents a 1.72% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Anne Lesage sold 30,703 shares of Pharvaris stock in a transaction on Tuesday, June 30th. The shares were sold at an average price of $35.49, for a total transaction of $1,089,649.47. Following the completion of the transaction, the insider owned 93,969 shares in the company, valued at approximately $3,334,959.81. This represents a 24.63% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 118,655 shares of company stock worth $4,188,002 in the last 90 days. 11.84% of the stock is owned by insiders.

Pharvaris Stock Up 0.7%

Shares of NASDAQ PHVS opened at $35.17 on Thursday. The business has a 50-day moving average price of $34.71 and a 200 day moving average price of $30.94. The stock has a market cap of $2.30 billion, a PE ratio of -11.53 and a beta of -2.33. Pharvaris N.V. has a 52-week low of $20.65 and a 52-week high of $38.13.

Pharvaris (NASDAQ:PHVS) last released its quarterly earnings results on Wednesday, August 12th. The company reported ($0.81) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.06). Sell-side analysts anticipate that Pharvaris N.V. will post -3.15 earnings per share for the current year.

About Pharvaris

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.